Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2017 Filed Feb 3, 2017 20:08 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000074 · wf-form4_148615248786775.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,732 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:08 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Tax withholdingCommon Stock | 4,570 | $77.03 | $352,027.10 |
DisclosureSEC source: 0000059478-17-000074 · wf-form4_148615248786775.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,470 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:08 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionCommon Stock | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000074 · wf-form4_148615248786775.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:11 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000076 · wf-form4_148615265019512.xml · derivative · entry 4 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,634 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:11 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 2,646 | $77.03 | $203,821.38 |
DisclosureSEC source: 0000059478-17-000076 · wf-form4_148615265019512.xml · nonDerivative · entry 2 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,312 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:11 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Exercise / conversionCommon Stock | 5,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000076 · wf-form4_148615265019512.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:13 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000078 · wf-form4_148615280511920.xml · derivative · entry 4 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,244 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:13 UTC |
Ricks David ADirector · President & CEO
|
Tax withholdingCommon Stock | 4,837 | $77.03 | $372,594.11 |
DisclosureSEC source: 0000059478-17-000078 · wf-form4_148615280511920.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,563 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:13 UTC |
Ricks David ADirector · President & CEO
|
Exercise / conversionCommon Stock | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000078 · wf-form4_148615280511920.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:16 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000080 · wf-form4_148615294662173.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,244 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:16 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Tax withholdingCommon Stock | 4,731 | $77.03 | $364,428.93 |
DisclosureSEC source: 0000059478-17-000080 · wf-form4_148615294662173.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,022 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:16 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
Exercise / conversionCommon Stock | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000080 · wf-form4_148615294662173.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:18 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000082 · wf-form4_148615308089978.xml · derivative · entry 6 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,610 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:18 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Tax withholdingCommon Stock | 2,165 | $77.03 | $166,769.95 |
DisclosureSEC source: 0000059478-17-000082 · wf-form4_148615308089978.xml · nonDerivative · entry 2 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,144 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:18 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Exercise / conversionCommon Stock | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000082 · wf-form4_148615308089978.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:20 UTC |
Zulueta Alfonso GSVP& Pres., Emerging Markets
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000084 · wf-form4_148615321334676.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,659 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:20 UTC |
Zulueta Alfonso GSVP& Pres., Emerging Markets
|
Tax withholdingCommon Stock | 3,127 | $77.03 | $240,872.81 |
DisclosureSEC source: 0000059478-17-000084 · wf-form4_148615321334676.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,583 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:20 UTC |
Zulueta Alfonso GSVP& Pres., Emerging Markets
|
Exercise / conversionCommon Stock | 6,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000084 · wf-form4_148615321334676.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:24 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000087 · wf-form4_148615345890925.xml · derivative · entry 4 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,073 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:24 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Tax withholdingCommon Stock | 1,420 | $77.03 | $109,382.60 |
DisclosureSEC source: 0000059478-17-000087 · wf-form4_148615345890925.xml · nonDerivative · entry 2 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,941 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:24 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionCommon Stock | 3,073 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000087 · wf-form4_148615345890925.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:20 UTC |
Rice Derica WEVP-Global Services and CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 19,463 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000089 · wf-form4_148616041253502.xml · derivative · entry 8 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,463 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:20 UTC |
Rice Derica WEVP-Global Services and CFO
|
Tax withholdingCommon Stock | 8,989 | $77.03 | $692,422.67 |
DisclosureSEC source: 0000059478-17-000089 · wf-form4_148616041253502.xml · nonDerivative · entry 2 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,454 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:20 UTC |
Rice Derica WEVP-Global Services and CFO
|
Exercise / conversionCommon Stock | 19,463 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000089 · wf-form4_148616041253502.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 23:36 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 142 | $76.85 | $10,912.70 |
DisclosureSEC source: 0000059478-17-000057 · wf-form4_148590579106932.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,203 Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 23:40 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 126 | $76.85 | $9,683.10 |
DisclosureSEC source: 0000059478-17-000059 · wf-form4_148590603752112.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:47 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantRestricted Stock Unit · Derivative | 6,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000026 · wf-form4_148590284266649.xml · derivative · entry 3 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Underlying: Common Stock · 6,398 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:47 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 6,119 | $75.38 | $461,250.22 |
DisclosureSEC source: 0000059478-17-000026 · wf-form4_148590284266649.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,288 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:51 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000028 · wf-form4_148590304851291.xml · derivative · entry 3 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:51 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 20,211 | $75.38 | $1,523,505.18 |
DisclosureSEC source: 0000059478-17-000028 · wf-form4_148590304851291.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,783 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:53 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantRestricted Stock Unit · Derivative | 17,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000030 · wf-form4_148590317331791.xml · derivative · entry 2 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,060 Underlying: Common Stock · 17,060 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:53 UTC |
Crowe Maria APresident, Mfg. Operations
|
GrantCommon Stock | 16,634 | $75.38 | $1,253,870.92 |
DisclosureSEC source: 0000059478-17-000030 · wf-form4_148590317331791.xml · nonDerivative · entry 1 Crowe Maria A · CIK 0001538603 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,118 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:57 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 17,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000033 · wf-form4_148590342647109.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,060 Underlying: Common Stock · 17,060 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:57 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 15,179 | $75.38 | $1,144,193.02 |
DisclosureSEC source: 0000059478-17-000033 · wf-form4_148590342647109.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,869 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:03 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantRestricted Stock Unit · Derivative | 24,524 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000035 · wf-form4_148590381572425.xml · derivative · entry 3 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,524 Underlying: Common Stock · 24,524 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:03 UTC |
Harrington Michael JSenior VP and General Counsel
|
GrantCommon Stock | 21,285 | $75.38 | $1,604,463.30 |
DisclosureSEC source: 0000059478-17-000035 · wf-form4_148590381572425.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,700 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:06 UTC |
LECHLEITER JOHN CDirector
|
GrantRestricted Stock Unit · Derivative | 106,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000037 · wf-form4_148590395176522.xml · derivative · entry 6 LECHLEITER JOHN C · CIK 0001209281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,625 Underlying: Common Stock · 106,625 shares Expires 2018-02-01 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:06 UTC |
LECHLEITER JOHN CDirector
|
GrantCommon Stock | 93,021 | $75.38 | $7,011,922.98 |
DisclosureSEC source: 0000059478-17-000037 · wf-form4_148590395176522.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,890 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:09 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 36,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000039 · wf-form4_148590415686193.xml · derivative · entry 3 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,252 Underlying: Common Stock · 36,252 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:09 UTC |
Lundberg Jan MEVP,Science&Tech and Pres. LRL
|
GrantCommon Stock | 32,268 | $75.38 | $2,432,361.84 |
DisclosureSEC source: 0000059478-17-000039 · wf-form4_148590415686193.xml · nonDerivative · entry 1 Lundberg Jan M · CIK 0001480120 · EVP,Science&Tech and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,002 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:13 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000041 · wf-form4_148590438218792.xml · derivative · entry 5 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:13 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 2,030 | $75.38 | $153,021.40 |
DisclosureSEC source: 0000059478-17-000041 · wf-form4_148590438218792.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 13,509 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:13 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
GrantCommon Stock | 19,243 | $75.38 | $1,450,537.34 |
DisclosureSEC source: 0000059478-17-000041 · wf-form4_148590438218792.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,308 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:16 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 11,729 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000043 · wf-form4_148590456696658.xml · derivative · entry 3 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,729 Underlying: Common Stock · 11,729 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:16 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
GrantCommon Stock | 11,116 | $75.38 | $837,924.08 |
DisclosureSEC source: 0000059478-17-000043 · wf-form4_148590456696658.xml · nonDerivative · entry 1 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,324 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:18 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantRestricted Stock Unit · Derivative | 40,518 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000045 · wf-form4_148590471096809.xml · derivative · entry 5 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,518 Underlying: Common Stock · 40,518 shares Expires 2018-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:18 UTC |
Rice Derica WEVP-Global Services and CFO
|
GrantCommon Stock | 38,980 | $75.38 | $2,938,312.40 |
DisclosureSEC source: 0000059478-17-000045 · wf-form4_148590471096809.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,980 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:21 UTC |
Ricks David ADirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000047 · wf-form4_148590485372556.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:21 UTC |
Ricks David ADirector · President & CEO
|
GrantCommon Stock | 20,183 | $75.38 | $1,521,394.54 |
DisclosureSEC source: 0000059478-17-000047 · wf-form4_148590485372556.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,156 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:27 UTC |
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
|
GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000049 · wf-form4_148590508158714.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.